Research programme: vascular endothelial growth factor antagonists - Eyecopharm
Latest Information Update: 16 Mar 2011
At a glance
- Originator Ark Therapeutics
- Developer Eyecopharm
- Class
- Mechanism of Action Neuropilin-1 inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Age-related macular degeneration
Most Recent Events
- 16 Mar 2011 Discontinued - Preclinical for Age-related macular degeneration in Germany (Parenteral)
- 10 Oct 2007 Preclinical trials in Age-related macular degeneration in Germany (Parenteral)
- 26 Apr 2007 Preclinical trials in Macular degeneration in United Kingdom (Parenteral)